Rubicon Research
Rubicon Research Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Revenue growth remains strong and broad-based, driven by a specialty and differentiated product portfolio. Rubicon Research demonstrated strong Q1 FY27 performance with 51% YoY revenue growth, 65% EBITDA growth, and 95% PAT growth, indicating robust earnings momentum.
From Rubicon Research's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Revenue growth remains strong and broad-based, driven by a specialty and differentiated product portfolio.
- USD revenue for Q1 was $55 million, up 32% year-on-year, despite a slight sequential drop due to tactical measures.
- Expect strong revenue traction in coming quarters with a continued focus on higher margin specialty products.
- Product commercialization rate remains strong at 88%, supporting sustained revenue growth.
- New facility ramp-up at Pithampur expected to start commercialization in calendar year 2027 with significant capacity expansion headroom available for medium to long term growth.
- Pipeline and approvals are on track as per plan, supporting future revenue expansion.
- Increasing R&D spend (~INR 500 crores over nine quarters) fueling future product launches and revenue streams.
- Emphasis on value-added products and reduced reliance on lower-margin, outsourced manufacturing to enhance margins alongside growth.
Profitability & Margins
See what Rubicon Research said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Pithampur facility has around INR 1,500 million capital sitting pre-revenue with commercialization and ramp-up expected from Q1; capacity utilization is planned to scale up gradually over the next 6-12 months.
- The Pithampur site spans nearly 30 acres, with only 5-6 acres currently utilized, leaving significant headroom for quick capacity expansion over the next 2-3 years.
- Manufacturing infrastructure investments are strategically aligned with product portfolio needs and involve capacity expansion as revenue visibility increases.
- The company follows a portfolio-based CMO/manufacturing strategy balancing risk diversification and capacity building.
- R&D spend is targeted at INR 500 crores over nine quarters, maintaining 10-11% of sales, aimed at long-term high innovation products.
- Recent acquisitions, including the US manufacturing facility obtained via a court-supervised bankruptcy at a low cost, are part of strategic long-term value creation, with plans to build on these to create significant revenue and profit multipliers.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rubicon Research said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company shared that they provide updates on specialty portfolio gross profit and number of specialty products once a year.
- There was no specific numerical disclosure regarding the current or expected order book or pending orders in the provided transcript.
- Management emphasized consistent revenue growth and strong visibility for revenue in coming quarters but did not quantify pending orders.
- The ramp-up of the Pithampur manufacturing facility is planned for the next 6-12 months, indicating expected volume increase tied to orders.
- The focus remains on securing higher margin business and selectively letting go of lower margin contracts, implying a qualitative improvement in order book quality.
- No exact figures on order backlog or pending orders were shared in this call or related discussion.
Rubicon Research — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Rubicon Research Q1 FY27 results?
Revenue growth remains strong and broad-based, driven by a specialty and differentiated product portfolio. Rubicon Research demonstrated strong Q1 FY27 performance with 51% YoY revenue growth, 65% EBITDA growth, and 95% PAT growth, indicating robust earnings momentum.
What is Rubicon Research share price analysis?
Rubicon Research currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 99.0 with a market cap of ₹28,549 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research planning capital expenditure?
The Pithampur facility has around INR 1,500 million capital sitting pre-revenue with commercialization and ramp-up expected from Q1; capacity utilization is planned to scale up gradually over the next 6-12 months.
Keep Rubicon Research on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.